Shares last traded at $14.45 impressively higher than $11.44, the 50 day moving average and which is quite a bit higher than the 200 day moving average of $7.79. The 50 day moving average was up $3.01 and the 200 day average went up $6.66 or +85.42%. Trading volume for Sangamo Therapeutics, Inc. was 1,502K in the last trading session. Volume was down 9.70% under the stocks average daily volume.
Traders are a little more bullish on shares of the company considering the downtick in short interest. The stock experienced a fall in short interest of -5.10% as of the latest report on August 31, 2017. Short shares fell from 8,060,958 to 7,649,791 over that period. With short interest at 7,649,791 and short average daily volume at 1,559,946, the short-interest ratio is 5.0 and the percentage of shorted shares was 0.11% on August 31.
There has been some selling insider activity on Sangamo Therapeutics, Inc. (NASDAQ:SGMO) recently. Curt A. Iii Herberts, Sr.VP & Chief Business Officer disclosed the sale of 15,000 shares of SGMO stock. The shares were purchased at an average price of $15.00. The Sr.VP & Chief Business Officer now owns $237,495 of the stock per the Form 4 SEC filing. Curt A. Iii Herberts, Sr.VP & Chief Business Officer disclosed the sale of 15,000 shares of (SGMO). The shares were sold on July 14th for an average price of $10.00. Herberts now owns $205,170 of the stock according to the SEC filing.
Additionally, here are a few investment firms who have increased or decreased their stake in (SGMO). As of the end of the quarter Opaleye Management Inc. had sold a total of 1,000 shares trimming its holdings by 0.2%. The value of the company’s investment in Sangamo Therapeutics, Inc. increased from $3,021,000 to $5,104,000 a change of 69.0% for the reporting period. Iguana Healthcare Management, LLC expanded its holdings by buying 65,000 shares an increase of 43.3%. Iguana Healthcare Management, LLC owns 215,000 shares with a value of $1,892,000. The total value of its holdings increased 142.6%.
Trexquant Investment Lp bolstered its ownership by buying 66,526 shares an increase of 417.0% from 09/30/2016 to 06/30/2017. Trexquant Investment Lp now controls 82,478 shares worth $726,000. The value of the position overall is up by 881.1%. Ubs Group Ag augmented its position by buying 23,708 shares an increase of 346.1% in the quarter. Ubs Group Ag claims 30,558 shares valued at $269,000. The value of the position overall is up by 647.2%.
As of the last earnings report the EPS was $-0.81 and is projected to be $-0.82 for the current year with 83,610,000 shares presently outstanding. Next quarter’s EPS is estimated at $-0.22 with next year’s EPS anticipated to be $-0.80.
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., launched on June 22, 1995, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Business’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Business’s product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC..